Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Depreciation & Amortization (CF) (2024 - 2025)

Caris Life Sciences has reported Depreciation & Amortization (CF) over the past 2 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $4.3 million for Q4 2025, down 52.34% from a year ago — trailing twelve months through Dec 2025 was $24.7 million (changed N/A YoY), and the annual figure for FY2025 was $22.6 million, down 53.75%.
  • Depreciation & Amortization (CF) for Q4 2025 was $4.3 million at Caris Life Sciences, down from $4.9 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CAI hit a ceiling of $11.6 million in Q2 2024 and a floor of $4.3 million in Q4 2025.